Articles tagged with Cancer Medication
Researchers have developed a new therapy using tri-specific natural killer engagers (TriKE) to activate the patient's immune cells to attack cancer. The Phase I clinical trial aims to treat Acute Myeloid Leukemia (AML), a common and aggressive form of leukemia.
Researchers at LSU Health found that metformin can delay mammary gland development, enhance tumor growth and metastasis, and decrease AMPK activation. The study suggests metformin's therapeutic value in treating breast cancer in patients with low Nischarin expression levels.
A study has identified a potential new drug target in the fight against cancer by targeting a protein that blocks the primary gateways in mitochondria. The research found that mitoNEET can close voltage-dependent anion channels (VDACs), which normally allow metabolites and signaling molecules to pass through.
A recent study found that around half of cancer drug trials approved in Europe between 2014 and 2016 were at high risk of bias, indicating potential exaggeration of treatment effects. The findings highlight the need for improved trial design and reporting to ensure real benefits for patients.
Researchers found that targeting IL23, an immune molecule central to osteosarcoma development, can successfully shrink tumours in mice. The study provides hope for new treatments and repurposed therapy for this rare form of cancer.
A recent study by the SWOG Cancer Research Network found that nearly half of phase 3 cancer clinical trials sponsored by the National Cancer Institute (NCI) were associated with new cancer care guidelines or new drug approvals. The analysis suggests that NCTN trials contribute to cost-effective evidence guiding cancer patient care.
A new study found that combining a G12C KRAS inhibitor with two other compounds can significantly shrink lung tumours in mice and human cancer cells. This combination block the mTOR and IGF1R pathways, making it a promising avenue for treating lung adenocarcinomas with the deadly G12C KRAS mutation.
Patrick Sung, a leading BRCA expert, has received the National Cancer Institute's Outstanding Investigator Award, providing $6.1 million through 2026. His work focuses on understanding BRCA biology and its role in cancer initiation and progression.
SU2C Catalyst teams investigate new treatments for triple-negative breast cancer and metastatic hormone-sensitive prostate cancer, combining medicines like atezolizumab and ipatasertib with radiation and hormone therapy.
A study found that men with the BRCA2 gene fault are almost twice as likely to be diagnosed with prostate cancer and develop more serious tumours. Regular PSA testing could help detect these cancers earlier.
A $3 million Stand Up 2 Cancer grant supports a clinical trial evaluating a combination therapy to prevent triple-negative breast cancer recurrence. The trial will utilize a blood test to identify women at risk and harness the immune system to eliminate the cancer.
Biomedical engineers at Duke University developed a method to overcome limitations of gene-targeted cancer drugs by combining CRISPR/Cas9 targeting with sustained release drug delivery. This strategy effectively addressed potency, elimination, and resistance issues, demonstrating improved efficacy in mice with colorectal cancers.
Researchers at The Institute of Cancer Research have discovered the three-dimensional structure and function of the 'mix n match' protein DHX8, which helps control a process linked to cancer progression and drug resistance. This study opens up a potentially exciting new way to tackle drug-resistant cancers.
A new simulation software aims to enhance process knowledge and speed up biopharmaceutical manufacturing. Christian Witz's software shortens simulation times from months to hours, enabling more efficient troubleshooting and insights into processes.
A new study reveals that many cancer drug candidates fail in clinical trials due to off-target effects, rather than targeting essential molecular mechanisms. This unexpected finding challenges over 180 previous reports on the importance of specific proteins for cancer cell survival.
Researchers at Cold Spring Harbor Laboratory identified 10 cancer drugs that don't work as expected, revealing an off-target effect. The discovery highlights the need for more accurate mechanism of action understanding in personalized medicine.
New studies show that KRAS gene mutations, common in colorectal and other cancers, vary in disease severity depending on the specific mutation and tissue location. The findings suggest that precision medicine approaches must be tailored to individual mutant forms of KRAS.
Researchers at Yale Cancer Center have identified a key metabolic pathway that enables cancer cells to adapt to their microenvironment and respond to nutrient availability. The study suggests that targeting this pathway with drugs may help treat various forms of cancer by preventing cancer cells from growing in nutrient-rich environments.
A pilot study under the Lung Cancer Master Protocol (Lung-MAP) found that most cancer patients lack a clear understanding of their genomic test results. The study revealed serious knowledge gaps about the potential uses of gene sequencing results, with only 86% correctly knowing their test results would select their treatment regimen.
Scientists at Scripps Research Institute have developed a new method for creating hindered ethers, which are integral to many drugs and commercial products. The new method uses electrochemistry and has improved production yield and reduced expense compared to traditional methods.
A clinical study comparing liquid and tissue biopsies finds multiple resistance mechanisms in individual patients, which could explain why targeted therapies often fail. The results suggest possible molecular mechanisms underlying drug resistance, pointing the way to new and more personalized therapeutics.
Researchers at Cold Spring Harbor Laboratory have discovered a way to tackle the development of resistance in pancreatic cancer by targeting the ERBB signaling pathway. This approach has shown promise in shrinking pancreatic tumors in mice, providing a potential avenue for overcoming resistance and improving treatment outcomes.
The LIBRETTO-001 trial showed that selpercatinib achieved high response rates of up to 68% in patients with RET fusion-positive non-small cell lung cancer. The median duration of response was also notable at 20.3 months, with an intracranial objective response rate of 91%.
Gold-based molecules have shown to be up to 24 times more effective at killing cancer cells than cisplatin and inhibit tumour growth by up to 46.9%. They also target an enzyme linked with cancer progression and have anti-inflammatory properties.
A novel swallowable balloon device has been cleared by the FDA for clinical use, allowing for early detection of Barrett's esophagus and reducing the risk of esophageal adenocarcinoma. The test is more than 90% sensitive and non-invasive, making it a promising tool for screening and prevention.
The pending Altria-Juul deal could lead to increased e-cigarette use or less cigarette use, depending on regulations and policies. Georgetown University professor David Levy explores the motivations behind the $12.8 billion purchase and its potential impact on public health.
Scientists have identified a cellular pathway that allows acute myeloid leukemia cells to evade the effects of drugs. They then engineered a compound that targets this pathway, blocking a mutant protein and halting the cancer cells' ability to sidestep the compound's effects.
The USPSTF recommends medications like tamoxifen, raloxifene, or aromatase inhibitors to reduce breast cancer risk in asymptomatic women over 35 with increased risk but low adverse effects risk. The Task Force advises against routine use for women not at high breast cancer risk.
A new study reveals a shift in obesity-associated cancers towards younger individuals, with significant increases in certain types of cancers among non-Hispanic Black and Hispanic women and men. The study found that the number of cases of these cancers increased by 25% to 400% in specific populations between 2000 and 2016.
A large international study found that cardiovascular disease (CVD) remains the leading cause of death worldwide, but its share has declined in high-income countries where cancer deaths have become more frequent. CVD risk factors are highest in rich countries, yet mortality rates are lower, suggesting other factors may be at play.
Researchers at Imperial College London found that hormone treatments can induce a dormant state in breast cancer cells, known as 'sleeper cells'. This could provide clues to why some cancers become resistant to treatment and may lead to new ways of preventing recurrence. Further research is needed to unlock the secrets of these cells.
Researchers identify CDK7 as a key player in prostate cancer growth and development, offering new treatment hope for metastatic castration-resistant prostate cancer (CRPC). Turning off CDK7 leads to the death of cancer cells, with limited off-target effects on healthy cells.
Researchers identified a drug combination that significantly extends patient survival in lung transplant recipients, offering a potential solution to the median survival rate of less than six years after transplantation. Sirolimus plus tacrolimus was associated with a better median survival than MMF plus tacrolimus.
Researchers have developed a hydrogel-based carrier that can deliver siRNAs directly to tumors, overcoming the challenge of rapid degradation and limited cellular entry. This innovative technology has the potential to improve the effectiveness of siRNA-based cancer treatments and enable more efficient delivery of biologics.
Researchers identified a molecule called DCAF15 that makes cancer cells more susceptible to natural killer cells. Blocking this molecule could lead to better survival rates for patients with acute myeloid leukemia.
A new drug, TAK-228, has demonstrated effectiveness in treating metastatic bladder cancer, slowing tumor growth and progression. The study found that four of seven patients showed a positive response to the treatment.
Oncologists suggest using nab-paclitaxel instead of paclitaxel prior to surgery for high-risk breast cancer patients, potentially improving long-term outcomes and reducing disease recurrence. This approach may be particularly beneficial for women with hormone receptor positive, HER-2 negative breast cancer.
Researchers at Flinders University have isolated a compound from the Australian white rock sea snail with antibacterial and anti-inflammatory properties, as well as important anti-cancer effects. The compound, part of the indole class, shows promise for preventing colon cancer tumor formation.
A recent study found that primary care physicians recommend health promotion to at least some cancer survivors, but oncologists and specialists rarely do. Cancer survivors face increased risks of cardiovascular disease if they don't adopt healthy lifestyles.
Researchers discovered an antibody drug that can destroy immune cells surrounding solid tumours, allowing T-cells to attack and kill cancer cells more effectively. The approach could improve treatments for various types of cancer, including CAR-T therapy.
The National Institute on Minority Health and Health Disparities has funded 11 research centers in minority institutions to foster the next generation of researchers and address health disparities. The centers will focus on diseases disproportionately affecting minority populations, including cancer, cardiometabolic diseases, and HIV/A...
Researchers identified a unique way to disrupt cellular process contributing to Diffuse Intrinsic Pontine Gliomas (DIPG). A vulnerability in the metabolic process for creating NAD was found, allowing for potential targeting of cancer cells with PPM1D mutation.
Researchers compared three frontline breast cancer drugs and found significant differences in their biological activity. Abemaciclib was shown to be more effective than other drugs at high doses, affecting proteins beyond CDK4/6, suggesting it may work differently for patients who don't respond to other treatments.
A clinical trial discovered that selinexor, a novel therapy, effectively knocked down bone marrow cancer in over a quarter of patients, including two who achieved complete remission. The treatment showed promise for patients resistant to multiple therapies and offered new hope for those with limited treatment options.
Researchers at CeMM Research Center have identified new targets for treating BAF mutant cancers by analyzing the effects of single subunit loss on chromatin accessibility and transcription. The study reveals that aberrant functions of remaining complexes may confer cancer-promoting properties, making them potentially druggable.
Researchers discovered a three-drug combination that sensitizes cancer cells to treatment, overcoming cross-therapy resistance. The approach involves time-sensitive administration of glucose-6-phosphate dehydrogenase inhibitors alongside other drugs.
Research found raised risks of blood clots, cardiomyopathy, and heart failure among cancer survivors, particularly those treated with chemotherapy. Long-term cardiovascular risks were elevated for over five years after diagnosis.
Researchers found that abemaciclib, a chemotherapeutic agent effective in breast cancer, has synergy when combined with HuR and YAP1 inhibitors to inhibit cell growth. The study suggests new targets for improving the efficacy of this drug and overcoming drug resistance in pancreatic cancer.
Researchers found that tumor cells depleted of ARID1A become highly sensitive to PARP inhibitor drugs after radiation treatment. This discovery could advance efforts to treat cancers resistant to current standard treatments.
A phase I trial is evaluating the combination of fecal transplants and immunotherapy for melanoma, with preliminary research suggesting a potential link between the human microbiome and treatment outcomes. Researchers aim to improve responses in 40-50% of patients treated with immunotherapy.
A recent study found that fewer than eight per cent of cancer drug trials included participation from all four major races in the US between 2008 and 2018. Black and Hispanic patients were particularly underrepresented, with rates of 22 per cent and 44 per cent respectively.
The observational study found significant changes in age distribution between obesity-associated and nonobesity-associated cancer cases over the 16-year period. The analysis revealed notable sex and racial disparities, with certain populations experiencing a higher risk of developing obesity-associated cancers at younger ages.
Researchers have identified a combination of treatments that may be more powerful than current therapy alone for children with Ewing sarcoma. The new approach combines FAK inhibitors with aurora kinase B targets to kill cancer cells and inhibit tumor progression.
Researchers at UCLA have developed a nanoscale capsule that breaks through the blood-brain barrier, allowing it to reach and treat cancer that has spread to the central nervous system. In mouse studies, this capsule delivered cancer-fighting drugs effectively eliminating B-cell lymphoma tumors.
A phase 1 clinical trial found that combining AZD1775, a Wee1 inhibitor, with radiation and gemcitabine resulted in better-than-expected overall survival in patients with locally advanced pancreatic cancer. The median overall survival was 22 months, surpassing previous results for the same treatment combination.
A University of Minnesota study found that high-fat foods significantly increase cannabidiol (CBD) absorption into the body. CBD exposure is vastly increased when taken with high fatty foods, and concentrations in the blood can be four times higher than fasting levels.
The study found that ERK was easily switched on in ancient one-celled creatures but carefully restrained as animals evolved. Researchers identified two key changes that likely brought ERK under more control across evolution.
A ketogenic diet has been shown to inhibit the growth of squamous cell carcinoma tumors in mice with lung cancer. The study also found a correlation between high blood glucose levels and poor survival among patients with squamous cell carcinoma.
The study examined 3,368 medical aid in dying prescriptions from Oregon (1998-2017) and Washington (2009-2017), finding that most patients were insured, non-Hispanic white individuals with cancer. The primary reasons for pursuing medical aid in dying were loss of autonomy, impaired quality of life, and loss of dignity.
Researchers develop innovative technology to transform proteins and antibodies into stable drug transporters, reducing side effects and increasing effectiveness in targeted cancer treatment. The new method allows for lower doses and fewer severe side effects compared to existing antibody-drug conjugates.